|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00848224 |
|
Date of registration:
|
18/02/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Improving Adherence to Pharmacological Treatment
PACT |
|
Scientific title:
|
Improving Adherence to Pharmacological Treatment |
|
Date of first enrolment:
|
September 2000 |
|
Target sample size:
|
689 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00848224 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Ira S Ockene, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Massachusetts, Worcester |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- was between 30 and 85 years of age;
- had known CHD, defined as the presence of at least one coronary lesion at coronary
angiography of >50%.
Exclusion Criteria:
- was unable or unwilling to give informed consent;
- had a history of intolerance to two or more statin drugs;
- planned to move out of the area within one year of recruitment;
- had a poor prognosis such that life expectancy was thought to be <5 years;
- had a psychiatric illness which limited ability to participate; or
- had no telephone.
Age minimum:
30 Years
Age maximum:
85 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Medication Adherence
|
|
Intervention(s)
|
|
Behavioral: systems-based and pharmacist-mediated program
|
|
Primary Outcome(s)
|
|
The primary outcome evaluated is the percentage of patients with a serum low-density lipoprotein cholesterol (LDL-C) level <70 mg/dl.
[Time Frame: One year]
|
|
Secondary Outcome(s)
|
|
Proportion of prescribed lipid-lowering medication taken by patients as measured by a continuous multiple-interval (CMA) measure of medication availability based on pharmacy records.
[Time Frame: One year]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|